After obtaining European marketing authorisations (MA) for Sanofi’s injectable acetylsalicylic acid (formerly Kardegic® and Aspegic® injectables) a year earlier, Panpharma reached another major milestone at the end of 2024 by acquiring the German marketing authorisation for Bayer’s injectable acetylsalicylic acid (formerly Aspirin® I.V).
This medicine, recognised for its major therapeutic value in cardiology, will thus join Panpharma’s portfolio, with production entrusted to its Beignon site, a guarantee of French industrial expertise and pharmaceutical excellence.